Cosmo Pharmaceuticals improve people's lives by developing innovative treatments that address significant unmet clinical needs and improve clinical outcomes in the field of gastroenterology and endoscopy. Our clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases and Colon Infections. Our effort is aimed to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection rate of pre-cancerous lesions during colonoscopy. Along with our presence in drugs manufacturing, we have significant innovative research and operations supporting our growing portfolio of specialty products. Learn more at www.cosmopharma.com/.
$25M sweet spot round size
1997
$25M
from investors over 1 rounds
Cosmo Pharmaceuticals raised $25M on July 4, 2020